JP2016519763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519763A5 JP2016519763A5 JP2016503081A JP2016503081A JP2016519763A5 JP 2016519763 A5 JP2016519763 A5 JP 2016519763A5 JP 2016503081 A JP2016503081 A JP 2016503081A JP 2016503081 A JP2016503081 A JP 2016503081A JP 2016519763 A5 JP2016519763 A5 JP 2016519763A5
- Authority
- JP
- Japan
- Prior art keywords
- lung disease
- fibrotic lung
- expression level
- subject
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019693 Lung disease Diseases 0.000 claims 50
- 230000003176 fibrotic effect Effects 0.000 claims 49
- 108090000623 proteins and genes Proteins 0.000 claims 41
- 102000004169 proteins and genes Human genes 0.000 claims 39
- 239000003550 marker Substances 0.000 claims 24
- 239000012472 biological sample Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000000750 progressive effect Effects 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 230000009266 disease activity Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801290P | 2013-03-15 | 2013-03-15 | |
| US201361801476P | 2013-03-15 | 2013-03-15 | |
| US61/801,290 | 2013-03-15 | ||
| US61/801,476 | 2013-03-15 | ||
| US201361874947P | 2013-09-06 | 2013-09-06 | |
| US61/874,947 | 2013-09-06 | ||
| PCT/US2014/029392 WO2014144821A1 (en) | 2013-03-15 | 2014-03-14 | Proteomic ipf markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519763A JP2016519763A (ja) | 2016-07-07 |
| JP2016519763A5 true JP2016519763A5 (https=) | 2017-04-13 |
Family
ID=51537804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503081A Pending JP2016519763A (ja) | 2013-03-15 | 2014-03-14 | プロテオームｉｐｆマーカー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9726677B2 (https=) |
| EP (1) | EP2972392A4 (https=) |
| JP (1) | JP2016519763A (https=) |
| KR (1) | KR20150130408A (https=) |
| CN (1) | CN105122068A (https=) |
| BR (1) | BR112015023699A2 (https=) |
| CA (1) | CA2901384A1 (https=) |
| HK (1) | HK1219533A1 (https=) |
| MX (1) | MX2015012778A (https=) |
| RU (1) | RU2015144149A (https=) |
| WO (1) | WO2014144821A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
| HK1219533A1 (zh) | 2013-03-15 | 2017-04-07 | Intermune, Inc. | 蛋白质组学ipf标志物 |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US20170335396A1 (en) | 2014-11-05 | 2017-11-23 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| WO2018191747A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating pulmonary arterial hypertension |
| CN110945128B (zh) * | 2017-04-14 | 2023-11-03 | 代表亚利桑那大学的亚利桑那董事会 | 用于治疗肺纤维化的组合物和方法 |
| CN107677835B (zh) * | 2017-09-26 | 2019-08-09 | 上海市肺科医院 | 一种ae-ipf的蛋白标记物及其应用 |
| BR112021002728A2 (pt) * | 2018-08-17 | 2021-08-10 | F. Hoffmann-La Roche Ag | métodos de avaliação da fibrilação atrial, de auxílio à avaliação da fibrilação atrial, de diagnóstico de insuficiência cardíaca e de predição do risco de hospitalização, método implementado por computador para a avaliação da fibrilação atrial, kit e usos in vitro |
| EP3875958A4 (en) * | 2018-10-29 | 2022-10-05 | National University Corporation Tokyo Medical and Dental University | Method for obtaining information on risk of reduced respiratory function in patient with interstitial pneumonia, and use thereof |
| JP7300642B2 (ja) * | 2019-06-14 | 2023-06-30 | 国立大学法人浜松医科大学 | 特発性肺線維症の予後予測方法 |
| CN110333358A (zh) * | 2019-06-24 | 2019-10-15 | 浙江大学 | 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法 |
| WO2021024856A1 (ja) * | 2019-08-02 | 2021-02-11 | 国立医薬品食品衛生研究所長が代表する日本国 | 間質性肺炎のタンパク質診断バイオマーカー |
| CA3171622A1 (en) * | 2020-03-13 | 2021-09-16 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| WO2021210651A1 (ja) * | 2020-04-17 | 2021-10-21 | 国立医薬品食品衛生研究所長が代表する日本国 | 重症薬疹のタンパク質診断バイオマーカー |
| CN113607955A (zh) * | 2020-09-16 | 2021-11-05 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用 |
| CN113533750A (zh) * | 2020-10-22 | 2021-10-22 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 一种区分新型冠状病毒肺炎患者与健康者的系统 |
| WO2023038416A1 (ko) * | 2021-09-07 | 2023-03-16 | 주식회사 에프엔씨티바이오텍 | 폐 섬유증의 바이오마커 및 치료 표적으로서 csf3r |
| US20230147720A1 (en) * | 2021-11-05 | 2023-05-11 | Spiritus Therapeutics, Inc. | Purified Enriched Population Exosomes Derived From Individuals With A Chronic Progressive Lung Disease For Noninvasive Detection, Staging, And Medical Monitoring Of Disease Progression |
| CN114563562A (zh) * | 2022-03-01 | 2022-05-31 | 复旦大学附属中山医院 | Prdx6联合铁离子检测在ards进程监测中的应用 |
| KR102907646B1 (ko) * | 2022-08-19 | 2026-01-05 | 울산대학교 산학협력단 | 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커 |
| CN119947728A (zh) * | 2022-09-28 | 2025-05-06 | 勃林格殷格翰国际有限公司 | 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途 |
| CN117025745B (zh) * | 2022-11-18 | 2024-02-23 | 中国医学科学院北京协和医院 | 分子标志物在诊断干燥综合征中的应用 |
| WO2026069490A1 (ja) * | 2024-09-25 | 2026-04-02 | 国立大学法人大阪大学 | 進行性肺線維症診断用バイオマーカー、該バイオマーカーを用いた進行性肺線維症の検査方法及びそれらの利用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
| AU2002307494A1 (en) * | 2001-04-24 | 2002-11-05 | Bayer Corporation | Human timp-1 antibodies |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| WO2004009776A2 (en) * | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| US7888485B2 (en) * | 2003-03-26 | 2011-02-15 | Georgetown University | Anti-pleiotrophin antibodies and methods of use thereof |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| EP1626279B1 (en) * | 2004-08-12 | 2008-04-16 | Roche Diagnostics GmbH | Method for diagnosing liver fibrosis |
| CN101160528A (zh) * | 2005-02-14 | 2008-04-09 | 惠氏公司 | Il17-f在诊断和治疗气道炎症中的用途 |
| EP1757940A1 (en) * | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| US20110129845A1 (en) * | 2007-01-29 | 2011-06-02 | Crc For Asthma And Airways Ltd. | Method of diagnosis |
| WO2009028158A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2010028274A1 (en) * | 2008-09-05 | 2010-03-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation |
| US8568996B2 (en) * | 2008-10-21 | 2013-10-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | MMP activation peptide detection in biological samples |
| US20110280865A1 (en) * | 2009-01-16 | 2011-11-17 | The Ohio State University | Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof |
| WO2010102167A1 (en) * | 2009-03-05 | 2010-09-10 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| WO2010111625A1 (en) * | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| NZ625850A (en) * | 2009-08-21 | 2015-12-24 | Gilead Biologics Inc | Methods and compositions for treatment of pulmonary fibrotic disorders |
| US20120282276A1 (en) * | 2009-11-05 | 2012-11-08 | The Regents Of The University Of Michigan | Biomarkers predictive of progression of fibrosis |
| WO2011091270A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of Michigan | Biomarkers for lung disease monitoring |
| SG11201400724SA (en) * | 2011-09-19 | 2014-04-28 | Genentech Inc | Combination treatments comprising c-met antagonists and b-raf antagonists |
| HK1219533A1 (zh) | 2013-03-15 | 2017-04-07 | Intermune, Inc. | 蛋白质组学ipf标志物 |
-
2014
- 2014-03-14 HK HK16107519.9A patent/HK1219533A1/zh unknown
- 2014-03-14 MX MX2015012778A patent/MX2015012778A/es unknown
- 2014-03-14 BR BR112015023699A patent/BR112015023699A2/pt not_active IP Right Cessation
- 2014-03-14 CA CA2901384A patent/CA2901384A1/en not_active Abandoned
- 2014-03-14 US US14/213,970 patent/US9726677B2/en active Active - Reinstated
- 2014-03-14 JP JP2016503081A patent/JP2016519763A/ja active Pending
- 2014-03-14 EP EP14762377.1A patent/EP2972392A4/en not_active Withdrawn
- 2014-03-14 RU RU2015144149A patent/RU2015144149A/ru unknown
- 2014-03-14 KR KR1020157027988A patent/KR20150130408A/ko not_active Withdrawn
- 2014-03-14 CN CN201480021359.5A patent/CN105122068A/zh active Pending
- 2014-03-14 WO PCT/US2014/029392 patent/WO2014144821A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519763A5 (https=) | ||
| RU2015144149A (ru) | Протеомные маркеры илф | |
| Adams et al. | Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium | |
| Wigén et al. | Converging pathways in pulmonary fibrosis and Covid-19-the fibrotic link to disease severity | |
| Batista Jr et al. | Exercise training changes IL-10/TNF-α ratio in the skeletal muscle of post-MI rats | |
| CN107073120B (zh) | 抗流感病毒剂及抗流感病毒剂的筛选方法 | |
| Arron et al. | Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma | |
| Gong et al. | Interplay of VEGFa and MMP2 regulates invasion of glioblastoma | |
| US20210260113A1 (en) | Devices, methods, compositions and systems for the treatment of aging and age-related disorders | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP2017538671A5 (https=) | ||
| Lim et al. | Inflammatory fibroblasts in cancer | |
| Staloch et al. | Gremlin is a key pro-fibrogenic factor in chronic pancreatitis | |
| KR20230169484A (ko) | 미오스타틴 억제제의 용도 및 조합 요법 | |
| JP2015521050A5 (https=) | ||
| JP2012532628A5 (https=) | ||
| JP2008536480A5 (https=) | ||
| Batchu et al. | Lung and kidney ACE2 and TMPRSS2 in renin-angiotensin system blocker–treated comorbid diabetic mice mimicking host factors that have been linked to severe COVID-19 | |
| JP2016522163A5 (https=) | ||
| JP2015505245A5 (https=) | ||
| Singh et al. | Idiopathic pulmonary fibrosis: where do we stand and how far to go | |
| JP2018504909A5 (https=) | ||
| D’Haese et al. | The impact of MFG-E8 in chronic pancreatitis: potential for future immunotherapy? |